Upregulated miR‑203a‑3p and its potential molecular mechanism in breast cancer: A study based on bioinformatics analyses and a comprehensive meta‑analysis

Cai,Kai‑Teng; Feng,Cai‑Xia; Zhao,Jin‑Che; He,Rong‑Quan; Ma,Jie; Zhong,Jin‑Cai

doi:10.3892/mmr.2018.9543

Upregulated miR‑203a‑3p and its potential molecular mechanism in breast cancer: A study based on bioinformatics analyses and a comprehensive meta‑analysis

Authors:
- Kai‑Teng Cai
- Cai‑Xia Feng
- Jin‑Che Zhao
- Rong‑Quan He
- Jie Ma
- Jin‑Cai Zhong
View Affiliations

Affiliations: Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: October 10, 2018 https://doi.org/10.3892/mmr.2018.9543
Pages: 4994-5008
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) has been identified as the leading malignancy in women worldwide. However, the potential molecular mechanism of microRNA (miR)‑203a‑3p in BC remains to be elucidated. The present study evaluated the expression of miR‑203a‑3p in BC and adjacent normal tissue in several publically available datasets. The distinguishability of precursor miR‑203a and miR‑203a‑3p in BC tissue and adjacent breast tissue was assessed using receiver operating characteristic (ROC) and summarized ROC (sROC) approaches. In addition, gene ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes pathway analysis and protein‑protein interaction analysis were performed to determine the potential molecular mechanism of miR‑203a‑3p in BC. It was identified that the expression of precursor miR‑203a was markedly upregulated in 1,077 BC tissue samples compared to 104 adjacent breast tissue samples from The Cancer Genome Atlas. Additionally, an increasing trend in miR‑203a‑3p expression was observed in 756 BC tissue samples compared with 76 adjacent breast tissue samples from the University of California Santa Cruz Xena project. In addition, a comprehensive meta‑analysis suggested that the expression of miR‑203a‑3p was markedly increased in 2,444 BC tissue samples compared with 559 adjacent breast tissue samples. The area under the curve of the ROC and sROC revealed that miR‑203a‑3p expression was able to distinguish between BC tissue and adjacent breast tissue. However, miR‑203a‑3p exhibited no prognostic value in BC. The results of GO enrichment demonstrated that the miR‑203a target genes were associated with ‘plasma membrane integrity’, ‘cell surface receptor linked signal and transduction’ and ‘3',5'‑cyclic nucleotide phosphodiesterase activity’. ‘Purine metabolism’ was identified as the pathway with the most enrichment of miR‑203a‑3p target genes in BC. The present study also identified insulin‑like growth factor receptor (IGF1) as a hub gene associated with miR‑203a in BC. In summary, miR‑203a‑3p may enhance the development and oncogenesis of BC, and IGF1 was defined as a hub gene of miR‑203a‑3p in BC.

View Figures

View References

1	Jalali C, Ghaderi B, Amini S, Abdi M and Roshani D: Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues. Saudi Med J. 37:624–630. 2016. View Article : Google Scholar : PubMed/NCBI
2	Liang Z and Xi Y: MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer. Chin J Nat Med. 14:881–887. 2016.PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
4	Shou D, Wen L, Song Z, Yin J, Sun Q and Gong W: Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. Oncotarget. 7:64505–64511. 2016. View Article : Google Scholar : PubMed/NCBI
5	Xing L, He Q, Wang YY, Li HY and Ren GS: Advances in the surgical treatment of breast cancer. Chin Clin Oncol. 5:342016. View Article : Google Scholar : PubMed/NCBI
6	Hennequin C, Barillot I, Azria D, Belkacémi Y, Bollet M, Chauvet B, Cowen D, Cutuli B, Fourquet A, Hannoun-Lévi JM, et al: Radiotherapy of breast cancer. Cancer Radiother. 20 Suppl:S139–S146. 2016.(In French). View Article : Google Scholar : PubMed/NCBI
7	Ejlertsen B: Adjuvant chemotherapy in early breast cancer. Dan Med J. 63:B52222016.PubMed/NCBI
8	Zhang X, Ren D, Guo L, Wang L, Wu S, Lin C, Ye L, Zhu J, Li J, Song L, et al: Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer. Breast Cancer Res. 19:152017. View Article : Google Scholar : PubMed/NCBI
9	Li Z and Kang Y: Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther. 161:79–96. 2016. View Article : Google Scholar : PubMed/NCBI
10	Song JL, Chen C, Yuan JP and Sun SR: Progress in the clinical detection of heterogeneity in breast cancer. Cancer Med. 5:3475–3488. 2016. View Article : Google Scholar : PubMed/NCBI
11	Shen H and Li Z: miRNAs in NMDA receptor-dependent synaptic plasticity and psychiatric disorders. Clin Sci (Lond). 130:1137–1146. 2016. View Article : Google Scholar : PubMed/NCBI
12	Su W, Aloi MS and Garden GA: MicroRNAs mediating CNS inflammation: Small regulators with powerful potential. Brain Behav Immun. 52:1–8. 2016. View Article : Google Scholar : PubMed/NCBI
13	Zhou W, Zou B, Liu L, Cui K, Gao J, Yuan S and Cong N: MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4. Oncotarget. 7:74059–74073. 2016. View Article : Google Scholar : PubMed/NCBI
14	Yang L, Liang H, Wang Y, Gao S, Yin K, Liu Z, Zheng X, Lv Y, Wang L, Zhang CY, et al: MiRNA-203 suppresses tumor cell proliferation, migration and invasion by targeting Slug in gastric cancer. Protein Cell. 7:383–387. 2016. View Article : Google Scholar : PubMed/NCBI
15	Gao Y, Feng B, Han S, Lu L, Chen Y, Chu X, Wang R and Chen L: MicroRNA-129 in human cancers: From tumorigenesis to clinical treatment. Cell Physiol Biochem. 39:2186–2202. 2016. View Article : Google Scholar : PubMed/NCBI
16	Ren W, Li C, Duan W, Du S, Yang F, Zhou J and Xing J: MicroRNA-613 represses prostate cancer cell proliferation and invasion through targeting Frizzled7. Biochem Biophys Res Commun. 469:633–638. 2016. View Article : Google Scholar : PubMed/NCBI
17	Hao W, Luo W, Bai M, Li J, Bai X, Guo J, Wu J and Wang M: MicroRNA-206 inhibited the progression of glioblastoma through BCL-2. J Mol Neurosci. 60:531–538. 2016. View Article : Google Scholar : PubMed/NCBI
18	Liang AL, Zhang TT, Zhou N, Wu CY, Lin MH and Liu YJ: MiRNA-10b sponge: An anti-breast cancer study in vitro. Oncol Rep. 35:1950–1958. 2016. View Article : Google Scholar : PubMed/NCBI
19	Du S, Li H, Sun X, Li D, Yang Y, Tao Z, Li Q and Liu K: MicroRNA-124 inhibits cell proliferation and migration by regulating SNAI2 in breast cancer. Oncol Rep. 36:3259–3266. 2016. View Article : Google Scholar : PubMed/NCBI
20	Wang L, Sun H, Wang X, Hou N, Zhao L, Tong D, He K, Yang Y, Song T, Yang J and Huang C: EGR1 mediates miR-203a suppress the hepatocellular carcinoma cells progression by targeting HOXD3 through EGFR signaling pathway. Oncotarget. 7:45302–45316. 2016.PubMed/NCBI
21	Gomes BC, Martins M, Lopes P, Morujão I, Oliveira M, Araújo A, Rueff J and Rodrigues AS: Prognostic value of microRNA-203a expression in breast cancer. Oncol Rep. 36:1748–1756. 2016. View Article : Google Scholar : PubMed/NCBI
22	Wu H and Zhang J: Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data. Gynecol Oncol. 149:592–597. 2018. View Article : Google Scholar : PubMed/NCBI
23	Nasif D, Campoy E, Laurito S, Branham R, Urrutia G, Roqué M and Branham MT: Epigenetic regulation of ID4 in breast cancer: Tumor suppressor or oncogene? Clin Epigenetics. 10:1112018. View Article : Google Scholar : PubMed/NCBI
24	Zhang J, Lan Q and Lin J: Identification of key gene modules for human osteosarcoma by co-expression analysis. World J Surg Oncol. 16:892018. View Article : Google Scholar : PubMed/NCBI
25	Wang YW, Zhang W and Ma R: Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data. Oncol Rep. 39:1003–1010. 2018.PubMed/NCBI
26	Hui HX, Hu ZW, Jiang C, Wu J, Gao Y and Wang XW: ZNF418 overexpression protects against gastric carcinoma and prompts a good prognosis. Onco Targets Ther. 11:2763–2770. 2018. View Article : Google Scholar : PubMed/NCBI
27	Wu N, Yan J, Han T, Zou J and Shen W: Integrated assessment of differentially expressed plasma microRNAs in subtypes of nonsyndromic orofacial clefts. Medicine (Baltimore). 97:e112242018. View Article : Google Scholar : PubMed/NCBI
28	Yan L, Zhan C, Wu J and Wang S: Expression profile analysis of head and neck squamous cell carcinomas using data from the cancer genome atlas. Mol Med Rep. 13:4259–4265. 2016. View Article : Google Scholar : PubMed/NCBI
29	Hou L, Lin Z, Ni Y, Wu Y, Chen D, Song L, Huang X, Hu H and Yang D: Microarray expression profiling and gene ontology analysis of long non-coding RNAs in spontaneously hypertensive rats and their potential roles in the pathogenesis of hypertension. Mol Med Rep. 13:295–300. 2016. View Article : Google Scholar : PubMed/NCBI
30	Li GM, Zhang CL, Rui RP, Sun B and Guo W: Bioinformatics analysis of common differential genes of coronary artery disease and ischemic cardiomyopathy. Eur Rev Med Pharmacol Sci. 22:3553–3569. 2018.PubMed/NCBI
31	Zhou W, Ma CX, Xing YZ and Yan ZY: Identification of candidate target genes of pituitary adenomas based on the DNA microarray. Mol Med Rep. 13:2182–2186. 2016. View Article : Google Scholar : PubMed/NCBI
32	Xu F, Gao F, Liu Y, Wang Z, Zhuang X, Qu Z, Ma H, Liu Y, Fu C, Zhang Q and Duan X: Bioinformatics analysis of molecular mechanisms involved in intervertebral disc degeneration induced by TNF-α and IL-1β. Mol Med Rep. 13:2925–2931. 2016. View Article : Google Scholar : PubMed/NCBI
33	Huo W, Du M, Pan X, Zhu X, Gao Y and Li Z: miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. FEBS Open Bio. 7:1085–1091. 2017. View Article : Google Scholar : PubMed/NCBI
34	Kara M, Yumrutas O, Ozcan O, Celik OI, Bozgeyik E, Bozgeyik I and Tasdemir S: Differential expressions of cancer-associated genes and their regulatory miRNAs in colorectal carcinoma. Gene. 567:81–86. 2015. View Article : Google Scholar : PubMed/NCBI
35	Liu W, Dong Z, Liang J, Guo X, Guo Y, Shen S, Kuang G and Guo W: Downregulation of potential tumor suppressor mir-203a by promoter methylation contributes to the invasiveness of gastric cardia adenocarcinoma. Cancer Invest. 34:506–516. 2016. View Article : Google Scholar : PubMed/NCBI
36	Riemann A, Reime S and Thews O: Hypoxia-related tumor acidosis affects MicroRNA expression pattern in prostate and breast tumor cells. Adv Exp Med Biol. 977:119–124. 2017. View Article : Google Scholar : PubMed/NCBI
37	Lin QH, Zhang KD, Duan HX, Liu MX, Wei WL and Cao Y: ERGIC3, which is regulated by miR-203a, is a potential biomarker for non-small cell lung cancer. Cancer Sci. 106:1463–1473. 2015. View Article : Google Scholar : PubMed/NCBI
38	Liu Y, Dong Z, Liang J, Guo Y, Guo X, Shen S, Kuang G and Guo W: Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development. Tumour Biol. 37:5621–5632. 2016. View Article : Google Scholar : PubMed/NCBI
39	Costa-Silva DR, Barros-Oliveira MD, Borges RS, Tavares CB, Borges US, Alves-Ribeiro FA, Silva VC and Silva BB: Insulin-like growth factor 1 gene polymorphism and breast cancer risk. An Acad Bras Cienc. 88:2349–2356. 2016. View Article : Google Scholar : PubMed/NCBI
40	De Santi M, Annibalini G, Barbieri E, Villarini A, Vallorani L, Contarelli S, Berrino F, Stocchi V and Brandi G: Human IGF1 pro-forms induce breast cancer cell proliferation via the IGF1 receptor. Cell Oncol (Dordr). 39:149–159. 2016. View Article : Google Scholar : PubMed/NCBI